TAG:
clinical laboratory scientists
Theranos: Many Questions, but Very Few Answers
By Mary Van Doren | From the Volume XXII No. 6 – April 20, 2015 Issue
WHEN A COMPANY THAT GOES PUBLIC WITH ITS GOALS, regularly and repeatedly declaring its lofty ambitions to do good for mankind by disrupting the status quo and replacing it with something new and wonderful, it invites itself to be judged by its actions and what it actually delivers. Since Thera…
Leveraging Testing Technology To Identify MRSA, C. Difficile
By Joseph Burns | From the Volume XX No. 3 – March 4, 2013 Issue
CEO SUMMARY: Probably the most challenging infections for hospitals to control and reduce are methicillin-resistant Staphylococcus aureus (MRSA) and Clostridium difficile (C. diff). The laboratory at one New York hospital introduced algorithms to screen for the presence of each i…
Pathologists Exploring Use of Diagnostic Teams
By Joseph Burns | From the Volume XXII No. 2 – January 26, 2015 Issue
CEO SUMMARY: In the search for ways to add more value to lab testing services, pathologists and lab administrators are considering organizing diagnostic management teams within their hospitals. Such teams focus on complex cases and include…
Theranos Pursues Different Business Plan in Arizona
By Robert Michel | From the Volume XXI No. 14 – October 13, 2014 Issue
CEO SUMMARY: Since its big public debut in late 2013, Theranos has been the subject of keen interest and much skepticism among pathologists and clinical laboratory professionals. Theranos is expanding its presence in Phoenix, Arizona. However, as it does, it looks more like a conventional…
My Visit to Walgreens for Theranos Lab Tests
By Robert Michel | From the Volume XXI No. 11 – August 11, 2014 Issue
CEO SUMMARY: One of the biggest unknowns in the lab testing industry today is Theranos, the lab testing company based in Palo Alto, California. It says its proprietary technology is poised to transform the lab testing experience for patients and physicians. It says it can perform hundreds…
Could Health Insurers Be at War with Clinical Labs?
By Robert Michel | From the Volume XXI No. 8 – June 9, 2014 Issue
CEO SUMMARY: It may sound ridiculous to assert that the nation’s largest health insurers are now “waging war” against clinical labs. However, some very smart people in the profession of laboratory medicine are expressing this opinion. To support such a conclusion, they point to paye…
‘Game Changer’ Mass Spectrometry for Microbiology at UNC
By Joseph Burns | From the Volume XXI No. 8 – June 9, 2014 Issue
CEO SUMMARY: Microbiologists at the University of North Carolina are using MALDI-TOF mass spectrometry to slash the time to answer and significantly cut lab costs. Their goals are to improve patient outcomes and reduce average length of stay. In a one-year study presented last month, UNC …
LabCorp, Bio-Reference Labs, Epic, OHSU, Alberta Health
By Robert Michel | From the Volume XX, No. 17 – December 23, 2013 Issue
LABCORP, BRLI ISSUE REVISED GUIDANCE OF LOWER EARNINGS IN RECENT WEEKS, at least two public lab companies have issued downward earnings guidance for 2014. These changes are based, in part, on expected reimbursement reductions from the Medicare program. It was December 10 wh…
Pathologists in China, U.S. Linked By Digital Pathology
By Robert Michel | From the Volume XIX No. 12 – August 27, 2012 Issue
CEO Summary: It is one of the first clinical collaborations of this type to be anchored by use of digital pathology. Pathologists at the medical schools of the Second Affiliated Hospital of Zhejiang University in Hangzhou, China, and the University of California Los Angeles (UCLA) are exc…
Pathologists Can Offer ‘Companion Informatics’
By Joseph Burns | From the Volume XIX No. 9 – June 25, 2012 Issue
CEO SUMMARY: Community hospitals are recognizing increased interest in personalized medicine among consumers. One expert predicts that this will create opportunities for hospital labs and pathology groups to add value by offering subspecialty expertise in molecular diagnostics, genetic te…
CURRENT ISSUE

Volume XXXII, No. 6 – April 21, 2025
Now that a federal judge has vacated the FDA’s LDT rule, The Dark Report analyzes the judgement and notes the various steps the FDA could take in response. Also, lab testing at pharmacies is proving to be less successful than was once anticipated.
See the full table of contentsHow Much Laboratory Business Intelligence Have You Missed?
Lab leaders rely on THE DARK REPORT for actionable intelligence on important developments in the business of laboratory testing. Maximize the money you make-and the money you keep! Best of all, it is released every three weeks!
Sign up for TDR Insider
Join the Dark Intelligence Group FREE and get TDR Insider FREE!
Never miss a single update on the issues that matter to you and your business.
Topics
- Anatomic Pathology
- Clinical Chemistry
- Clinical Laboratory
- Clinical Laboratory Trends
- Digital Pathology
- Genetic Testing
- In Vitro Diagnostics
- IVD/Lab Informatics
- Lab Intelligence
- Lab Marketplace
- Lab Risk & Compliance
- Laboratory Automation
- Laboratory Billing
- Laboratory Compliance
- Laboratory Equipment
- Laboratory Information Systems
- Laboratory Management
- Lean Six Sigma
- Managed Care Contracts
- Molecular Diagnostics
- Pathology Trends
- People
- Uncategorized